宫颈癌的临床与影像学表现及其对FIGO和TNM分期的影响——来自EMBRACE研究的分析
该研究基于前瞻性观察性多中心EMBRACE研究,纳入1338例接受根治性放化疗的原发宫颈癌患者,比较临床检查与MRI的局部肿瘤分期差异,并比较FIGO 2009、FIGO 2018和TNM分期系统的分布差异。结果显示MRI与临床检查在364例(27.2%)患者中局部肿瘤分期不同,52%检出淋巴结转移;不同分期系统导致分期分布差异,TNM提供最细化的分期分配。
要点
- MRI与临床检查在27.2%(364/1338)的患者中局部肿瘤分期不同。
- 52%的患者检出淋巴结转移。
- FIGO 2009最常见分期为IIB(54%)和IIIB(16%);FIGO 2018为IIIC1(43%)和IIB(27%);TNM为T2b N0 M0(27%)和T2b N1 M0(23%)。
核心结论
- MRI与临床检查在约四分之一的患者中导致不同的局部肿瘤分期。
- 全面了解临床检查与MRI的鉴别价值对于确定最终局部分期是必要的,尤其在决定治疗方案时。
- 使用FIGO 2009、FIGO 2018和TNM分期系统导致分期分布差异,使治疗结果的可比性复杂化。
- TNM提供最细化的分期分配。
研究设计与样本
- 前瞻性观察性多中心研究EMBRACE,纳入1338例接受根治性放化疗的原发宫颈癌患者。
- 所有患者治疗前接受妇科检查和盆腔MRI;淋巴结状态通过MRI、CT、PET-CT或淋巴结切除术评估。
- 按FIGO 2009、FIGO 2018和TNM分期系统重新分期,分别评估MRI和临床检查的局部肿瘤分期,采用描述性统计比较。
主要发现
- 局部肿瘤分期中,MRI与临床检查在364例(27.2%)患者中存在差异。
- 52%的患者检出受累淋巴结。
- FIGO 2009分期中最常见的两个分期为IIB(54%)和IIIB(16%)。
- FIGO 2018分期中最常见的两个分期为IIIC1(43%)和IIB(27%)。
- TNM分期中最常见的两个分期为T2b N0 M0(27%)和T2b N1 M0(23%)。
关键数值与推荐
- MRI与临床检查局部肿瘤分期不一致的患者为364例(27.2%)。
- 淋巴结转移检出率为52%。
- FIGO 2009分期分布:IIB 54%,IIIB 16%。
- FIGO 2018分期分布:IIIC1 43%,IIB 27%。
- TNM分期分布:T2b N0 M0 27%,T2b N1 M0 23%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate differences in local tumour staging between clinical examination and MRI and differences between FIGO 2009, FIGO 2018 and TNM in patients with primary cervical cancer undergoing definitive radio-chemotherapy. METHODS: Patients from the prospective observational multi-centre study "EMBRACE" were considered for analysis. All patients had gynaecological examination and pelvic MRI before treatment. Nodal status was assessed by MRI, CT, PET-CT or lymphadenectomy. For this analysis, patients were restaged according to the FIGO 2009, FIGO 2018 and TNM staging system. The local tumour stage was evaluated for MRI and clinical examination separately. Descriptive statistics were used to compare local tumour stages and different staging systems. RESULTS: Data was available from 1338 patients. For local tumour staging, differences between MRI and clinical examination were found in 364 patients (27.2%). Affected lymph nodes were detected in 52%. The two most frequent stages with FIGO 2009 are IIB (54%) and IIIB (16%), with FIGO 2018 IIIC1 (43%) and IIB (27%) and with TNM T2b N0 M0 (27%) and T2b N1 M0 (23%) in this cohort. CONCLUSIONS: MRI and clinical examination resulted in a different local tumour staging in approximately one quarter of patients. Comprehensive knowledge of the differential value of clinical examination and MRI is necessary to define one final local stage, especially when a decision about treatment options is to be taken. The use of FIGO 2009, FIGO 2018 and TNM staging system leads to differences in stage distributions complicating comparability of treatment results. TNM provides the most differentiated stage allocation.
引用
- Knoth J, Pötter R, Jürgenliemk-Schulz IM, et al. Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging - An analysis from the EMBRACE study. Gynecol Oncol. 2020. PMID: 32798000. doi:10.1016/j.ygyno.2020.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。